Alligator Bioscience (STO:ATORX) has announced updated results from its Phase 2 OPTIMIZE-1 study evaluating mitazalimab in combination with chemotherapy as a first-line treatment for metastatic pancreatic cancer, highlighting encouraging overall survival (OS) benefit findings.
According to Alligator, these results reconfirm and extend the significant survival benefit and reinforce the potential of mitazalimab as a breakthrough immunotherapy candidate in pancreatic cancer.
In a statement, Soren Bregenholt, CEO of Alligator, said, “These 24-month data further validate mitazalimab’s potential to meaningfully impact treatment outcomes for pancreatic cancer patients, and the continued survival and response duration observed in the study reinforce our confidence in mitazalimab’s clinical promise and its potential to reshape the treatment landscape for this aggressive disease.”
“Moreover, the 400 µg/kg topline data suggest a positive dose-response correlation, further strengthening the rationale for developing mitazalimab at the 900 µg/kg dose,” he added.
